Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Masatoshi Kudo
Abstract
N/A
Topics & Concepts
DurvalumabTremelimumabMedicineHepatocellular carcinomaImmunotherapyNivolumabInternal medicineOncologyAtezolizumabGastroenterologyCancerIpilimumabHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersHepatitis B Virus Studies